Xu Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xu Zhang has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Mingming Liu
Institute of Microcirculation, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
5 shared publications - Su-Xia Wang
Laboratory of Electron Microscopy, Pathological Center, Peking University First Hospital
5 shared publications - Zhaohui Liu
Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China
5 shared publications - Ruijuan Xiu
Institute of Microcirculation, Chinese Academy of Medical Sciences & Peking Union Medical College
4 shared publications Bing Wang
Institute of Microcirculation, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China; International Center of Microvascular Medicine, Chinese Academy of Medical Sciences, Beijing 100005, China
3 shared publicationsTing Li
Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China
3 shared publications
Latest Publications
- Open Access
- 20 March 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (6) , e71098
Consequences of CRISPR ‐Cas9‐Mediated Stromelysin‐1 Knockout in Pancreatic Islet Microvascular Endothelial Cells
The integrity of the pancreatic islet microvasculature is critical for endocrine function, yet it is progressively compromised by glucotoxicity in diabetes. While matrix metalloproteinases are implicated, the role of stromelysin‐1 as a potential upstream driver of endothelial dysfunction remains poorly defined. The aim of our study was to elucidate the role of stromelysin‐1 in mediating glucotoxic injury to islet microvascular endothelial cells (IMECs). To this end, we employed a CRISPR/Cas9‐mediated knockout of stromelysin‐1 in IMECs. Cellular functions, including proliferation, migration, and angiogenesis, were assessed using IncuCyte ZOOM live‐cell imaging, while endothelial barrier integrity was quantified via a 40 kDa dextran flux assay. Additionally, the secretome was profiled using a cytokine antibody array. We found that genetic ablation of stromelysin‐1 conferred protection against glucotoxicity. Stromelysin‐1 KO IMECs exhibited significantly enhanced proliferation, migration, and angiogenic capacity compared to wild‐type controls. Furthermore, stromelysin‐1 deficiency restored endothelial monolayer integrity by attenuating high‐glucose‐induced hyperpermeability. These functional improvements were linked to a remodelling of the secretome, characterised by decreased secretion of the pro‐degradative MMP‐2 and increased secretion of the anti‐inflammatory cytokine IL‐10 and the endogenous inhibitor TIMP‐2. Overall, our findings establish stromelysin‐1 as a crucial mediator of glucotoxic injury in islet microvascular endothelial cells.
- 20 March 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (6) , e71098
Open AccessConsequences of CRISPR ‐Cas9‐Mediated Stromelysin‐1 Knockout in Pancreatic Islet Microvascular Endothelial Cells
The integrity of the pancreatic islet microvasculature is critical for endocrine function, yet it is progressively compromised by glucotoxicity in diabetes. While matrix metalloproteinases are implicated, the role of stromelysin‐1 as a potential upstream driver of endothelial dysfunction remains poorly defined. The aim of our study was to elucidate the role of stromelysin‐1 in mediating glucotoxic injury to islet microvascular endothelial cells (IMECs). To this end, we employed a CRISPR/Cas9‐mediated knockout of stromelysin‐1 in IMECs. Cellular functions, including proliferation, migration, and angiogenesis, were assessed using IncuCyte ZOOM live‐cell imaging, while endothelial barrier integrity was quantified via a 40 kDa dextran flux assay. Additionally, the secretome was profiled using a cytokine antibody array. We found that genetic ablation of stromelysin‐1 conferred protection against glucotoxicity. Stromelysin‐1 KO IMECs exhibited significantly enhanced proliferation, migration, and angiogenic capacity compared to wild‐type controls. Furthermore, stromelysin‐1 deficiency restored endothelial monolayer integrity by attenuating high‐glucose‐induced hyperpermeability. These functional improvements were linked to a remodelling of the secretome, characterised by decreased secretion of the pro‐degradative MMP‐2 and increased secretion of the anti‐inflammatory cytokine IL‐10 and the endogenous inhibitor TIMP‐2. Overall, our findings establish stromelysin‐1 as a crucial mediator of glucotoxic injury in islet microvascular endothelial cells.
- Open Access
- 26 February 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (5) , 4066-4081
Rapid improvement of renal microcirculatory homeostasis by liraglutide following diabetes induction
Aims: Renal microvascular dysfunction is a central driver of diabetic kidney disease, yet the potential for rapid therapeutic reversal remains obscure. We investigated the effect of short‐term liraglutide on early changes in the renal microcirculation post‐induction of diabetes. Materials and Methods: Type 2 diabetes mellitus (T2DM) was induced in BALB/c mice via high‐fat diet and streptozotocin. Following induction, mice received insulin or liraglutide treatments for 1 or 2 weeks. Renal microhemodynamics was analysed using laser Doppler flowmetry and wavelet analysis. Histopathological evaluations via Masson trichrome and haematoxylin–eosin staining assessed fibrosis and microvascular integrity. Primary renal microvascular endothelial cells (RMECs) were isolated to evaluate angiogenic and migratory behaviours. Metabolomics analyses were performed to link metabolic changes with microcirculatory alterations. Results: T2DM induced significant impairments in renal microcirculation, characterised by dysregulated microhemodynamics, disturbed oxygen saturation, altered haemoglobin distribution and compromised blood perfusion. These functional defects were accompanied by elevated creatinine, reduced cystatin C and impaired angiogenic and migratory capacity of RMECs under glucotoxicity. Both insulin and liraglutide treatments ameliorated renal microcirculatory oxygen profiles and improved renal function biomarkers. Histological data revealed decreased fibrosis and enhanced microvascular architecture post‐treatment. Metabolomic profiling revealed that liraglutide preferentially restored depleted amino acid levels associated with microvascular function, a change associated with the normalisation of metabolic profiles potentially involving peptide transport pathways. Conclusions: Our findings demonstrate that short‐term liraglutide restores renal microcirculatory homeostasis in the post‐induction phase, mitigating microvascular dysfunction and preserving kidney structure, highlighting the potential therapeutic value in preventing the progression of diabetic renal injury.
- 26 February 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (5) , 4066-4081
Open AccessRapid improvement of renal microcirculatory homeostasis by liraglutide following diabetes induction
Aims: Renal microvascular dysfunction is a central driver of diabetic kidney disease, yet the potential for rapid therapeutic reversal remains obscure. We investigated the effect of short‐term liraglutide on early changes in the renal microcirculation post‐induction of diabetes. Materials and Methods: Type 2 diabetes mellitus (T2DM) was induced in BALB/c mice via high‐fat diet and streptozotocin. Following induction, mice received insulin or liraglutide treatments for 1 or 2 weeks. Renal microhemodynamics was analysed using laser Doppler flowmetry and wavelet analysis. Histopathological evaluations via Masson trichrome and haematoxylin–eosin staining assessed fibrosis and microvascular integrity. Primary renal microvascular endothelial cells (RMECs) were isolated to evaluate angiogenic and migratory behaviours. Metabolomics analyses were performed to link metabolic changes with microcirculatory alterations. Results: T2DM induced significant impairments in renal microcirculation, characterised by dysregulated microhemodynamics, disturbed oxygen saturation, altered haemoglobin distribution and compromised blood perfusion. These functional defects were accompanied by elevated creatinine, reduced cystatin C and impaired angiogenic and migratory capacity of RMECs under glucotoxicity. Both insulin and liraglutide treatments ameliorated renal microcirculatory oxygen profiles and improved renal function biomarkers. Histological data revealed decreased fibrosis and enhanced microvascular architecture post‐treatment. Metabolomic profiling revealed that liraglutide preferentially restored depleted amino acid levels associated with microvascular function, a change associated with the normalisation of metabolic profiles potentially involving peptide transport pathways. Conclusions: Our findings demonstrate that short‐term liraglutide restores renal microcirculatory homeostasis in the post‐induction phase, mitigating microvascular dysfunction and preserving kidney structure, highlighting the potential therapeutic value in preventing the progression of diabetic renal injury.
- Open Access
- 1 July 2025
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 44 (4) , 626-637
NLRP3 inflammasome activation and macrophage distribution in kidney tissues from patients with acute oxalate nephropathy
Background: The current study was initiated to evaluate renal nucleotide-binding and oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome pathway activation and macrophage subtype distribution and their clinicopathological significance in a cohort of oxalate-induced acute kidney injury. Methods: Twelve patients with biopsy-proven acute oxalate nephropathy (AON) from January 2016 to October 2022 were retrospectively enrolled, with estimated glomerular filtration rate (eGFR)-matched 24 patients with acute tubulointerstitial nephritis (ATIN) as disease control. Pathological lesions as well as markers of NLRP3 inflammasome pathway and macrophage phenotype detected by immunohistochemistry staining were semi-quantitatively analyzed. Results: Oxalate depositions were found in 5% to 20% of tubules with a positive correlation with Sirius Red staining in AON specimens (rp = 0.668, p = 0.02). Disruption of tubular basement membrane and inflammatory cell reaction was more prominent in specimens of AON (both p < 0.05) as compared with ATIN specimens. The expressions of NLRP3, caspase-1, and gasdermin D were significantly increased in AON specimens as well (all p < 0.05). Patients with M1/M2 macrophage ratio <1 were found with more chronic tubulointerstitial lesions and presented with lower eGFR at the last follow-up (24.8 ± 10.6 mL/min/1.73 m2 vs. 55.1 ± 21.2 mL/ min/1.73 m2, p = 0.02) in the AON group. Conclusion: The NLRP3 inflammasome pathway was activated in the kidneys of AON patients, and the ratio of M1 and M2 macrophages was associated with chronicity of pathological changes, which needs further exploration.
- 1 July 2025
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 44 (4) , 626-637
Open AccessNLRP3 inflammasome activation and macrophage distribution in kidney tissues from patients with acute oxalate nephropathy
Background: The current study was initiated to evaluate renal nucleotide-binding and oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome pathway activation and macrophage subtype distribution and their clinicopathological significance in a cohort of oxalate-induced acute kidney injury. Methods: Twelve patients with biopsy-proven acute oxalate nephropathy (AON) from January 2016 to October 2022 were retrospectively enrolled, with estimated glomerular filtration rate (eGFR)-matched 24 patients with acute tubulointerstitial nephritis (ATIN) as disease control. Pathological lesions as well as markers of NLRP3 inflammasome pathway and macrophage phenotype detected by immunohistochemistry staining were semi-quantitatively analyzed. Results: Oxalate depositions were found in 5% to 20% of tubules with a positive correlation with Sirius Red staining in AON specimens (rp = 0.668, p = 0.02). Disruption of tubular basement membrane and inflammatory cell reaction was more prominent in specimens of AON (both p < 0.05) as compared with ATIN specimens. The expressions of NLRP3, caspase-1, and gasdermin D were significantly increased in AON specimens as well (all p < 0.05). Patients with M1/M2 macrophage ratio <1 were found with more chronic tubulointerstitial lesions and presented with lower eGFR at the last follow-up (24.8 ± 10.6 mL/min/1.73 m2 vs. 55.1 ± 21.2 mL/ min/1.73 m2, p = 0.02) in the AON group. Conclusion: The NLRP3 inflammasome pathway was activated in the kidneys of AON patients, and the ratio of M1 and M2 macrophages was associated with chronicity of pathological changes, which needs further exploration.
- 22 August 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (1) , 60-72
Lactobacillus casei Cell Wall Extract and Production of Galactose-Deficient IgA1 in a Humanized IGHA1 Mouse Model
Key Points: We generated a transgenic mouse model expressing the human IgA1 heavy chain, which has a hinge region with rich O-linked glycosylation. After inflammatory stimulation, the mouse model showed elevated galactose-deficient IgA1 levels in the serum. Coupled with complement H factor mutant, the mice model exhibited glomerular lesions, associated with hematuria and albuminuria like IgA nephropathy. Background: IgA nephropathy is the most common primary glomerulonephritis worldwide, and there is emerging evidence linking galactose-deficient IgA1 (Gd-IgA1) to the pathogenesis of the disease. However, mouse models that can be used to study Gd-IgA1's origin of production, biochemical characteristics, and immune reactivity are lacking. Methods: We generated a humanized IgA1 mouse model with transgenic expression of the human IGHA1 gene from the mouse chromosomal locus of IgA heavy chain. The IGHA1 +/+ mice were crossed with complement factor H heterozygous mutant (FHW/R) to generate IGHA1 +/+FHW /R mice. IGHA1 +/+ mice were exposed to different levels of environmental pathogens in the first 4 months, as housed in germ-free, specific pathogen–free, or conventional environments. In addition, wild-type C57BL/6J mice, IGHA1 +/+ mice, and IGHA1 +/+FHW/R mice were inoculated with Lactobacillus casei cell wall extract (LCWE) mixed with complete Freund's adjuvant (CFA) at 2 months of age to develop a mouse model of IgA nephropathy. Results: Elevated levels of human IgA1 in blood circulation and mucosal sites were observed in IGHA1 +/+ mice from exposure to pathogens. Compared with buffer-treated control mice, LCWE plus CFA-treated mice had moderately elevated levels of circulating human IgA1 (by one-fold) and human IgA1 immune complexes (by two-fold). Serum Gd-IgA1 levels increased four-fold after LCWE treatments. Analyses of the O-glycopeptides of the IgA1 hinge region confirmed hypogalactosylation of IgA1, with the variety of the glycoforms matching those seen in clinical samples. Furthermore, LCWE induced persistent IgA1 and C3 deposition in the glomerular mesangial areas in association with mesangial expansion and hypercellularity, which are frequently observed in IgA nephropathy biopsies. The IGHA1+/+FHW/R mice stimulated with LCWE and CFA developed albuminuria and hematuria. Conclusions: We observed elevated plasma Gd-IgA1 levels with kidney deposition of IgA1 in the IGHA1 +/+ mice after LCWE and CFA. In conjunction with factor H mutation, the mice exhibited severe glomerular alterations, associated with hematuria and albuminuria in resemblance of clinical IgA nephropathy.
- 22 August 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (1) , 60-72
Lactobacillus casei Cell Wall Extract and Production of Galactose-Deficient IgA1 in a Humanized IGHA1 Mouse Model
Key Points: We generated a transgenic mouse model expressing the human IgA1 heavy chain, which has a hinge region with rich O-linked glycosylation. After inflammatory stimulation, the mouse model showed elevated galactose-deficient IgA1 levels in the serum. Coupled with complement H factor mutant, the mice model exhibited glomerular lesions, associated with hematuria and albuminuria like IgA nephropathy. Background: IgA nephropathy is the most common primary glomerulonephritis worldwide, and there is emerging evidence linking galactose-deficient IgA1 (Gd-IgA1) to the pathogenesis of the disease. However, mouse models that can be used to study Gd-IgA1's origin of production, biochemical characteristics, and immune reactivity are lacking. Methods: We generated a humanized IgA1 mouse model with transgenic expression of the human IGHA1 gene from the mouse chromosomal locus of IgA heavy chain. The IGHA1 +/+ mice were crossed with complement factor H heterozygous mutant (FHW/R) to generate IGHA1 +/+FHW /R mice. IGHA1 +/+ mice were exposed to different levels of environmental pathogens in the first 4 months, as housed in germ-free, specific pathogen–free, or conventional environments. In addition, wild-type C57BL/6J mice, IGHA1 +/+ mice, and IGHA1 +/+FHW/R mice were inoculated with Lactobacillus casei cell wall extract (LCWE) mixed with complete Freund's adjuvant (CFA) at 2 months of age to develop a mouse model of IgA nephropathy. Results: Elevated levels of human IgA1 in blood circulation and mucosal sites were observed in IGHA1 +/+ mice from exposure to pathogens. Compared with buffer-treated control mice, LCWE plus CFA-treated mice had moderately elevated levels of circulating human IgA1 (by one-fold) and human IgA1 immune complexes (by two-fold). Serum Gd-IgA1 levels increased four-fold after LCWE treatments. Analyses of the O-glycopeptides of the IgA1 hinge region confirmed hypogalactosylation of IgA1, with the variety of the glycoforms matching those seen in clinical samples. Furthermore, LCWE induced persistent IgA1 and C3 deposition in the glomerular mesangial areas in association with mesangial expansion and hypercellularity, which are frequently observed in IgA nephropathy biopsies. The IGHA1+/+FHW/R mice stimulated with LCWE and CFA developed albuminuria and hematuria. Conclusions: We observed elevated plasma Gd-IgA1 levels with kidney deposition of IgA1 in the IGHA1 +/+ mice after LCWE and CFA. In conjunction with factor H mutation, the mice exhibited severe glomerular alterations, associated with hematuria and albuminuria in resemblance of clinical IgA nephropathy.
- Open Access
- 24 May 2024
- Published by Elsevier in Laboratory Investigation
- Vol. 104 (7) , 102087
Evaluation of Renal Microhemodynamics Heterogeneity in Different Strains and Sexes of Mice
- 24 May 2024
- Published by Elsevier in Laboratory Investigation
- Vol. 104 (7) , 102087
Open AccessEvaluation of Renal Microhemodynamics Heterogeneity in Different Strains and Sexes of Mice
- Open Access
- 1 May 2021
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 13, 3879-3888
Monoclonal Immunoglobulin-Associated Renal Lesions in Patients with Newly Diagnosed Multiple Myeloma: A Report from a Single Center
Background: Monoclonal immunoglobulin-associated renal lesions in patients with newly diagnosed myeloma vary. We aimed to determine the pathological spectrum and analyze associated prognostic factors. Methods: Fifty-six patients with newly diagnosed multiple myeloma and biopsy-proven renal lesions were enrolled. Kidney biopsies were reanalyzed, and the baseline clinical characteristics, treatments and outcomes were recorded. Results: Fifty-one patients had monoclonal immunoglobulin-associated renal lesions, with myeloma cast nephropathy (MCN) being the most common pattern. We divided our cohort into pure MCN, MCN+ other pathologies and non-MCN. Patients with MCN had more severe renal injury than those with non-MCN. In our cohort, none of the patients with pure MCN or MCN + other pathologies presented with nephrotic syndrome. Patients with non-MCN had better renal and overall survival than those with pure MCN but similar survivals to those with MCN + other pathologies. Number of myeloma casts (HR 1.08, p = 0.012) was the only independent prognostic factor for renal survival. Male sex (HR: 3.64; p = 0.015) and number of casts (HR: 1.17; p = 0.001) were independent prognostic factors for overall survival. Conclusion: Patients with MCN had more severe renal injury than those with non-MCN. Patients with non-MCN had better renal and overall outcomes than those with pure MCN, but their outcomes were similar to those with MCN + other pathologies. The independent predictors of overall survival were male sex and number of myeloma casts.
- 1 May 2021
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 13, 3879-3888
Open AccessMonoclonal Immunoglobulin-Associated Renal Lesions in Patients with Newly Diagnosed Multiple Myeloma: A Report from a Single Center
Background: Monoclonal immunoglobulin-associated renal lesions in patients with newly diagnosed myeloma vary. We aimed to determine the pathological spectrum and analyze associated prognostic factors. Methods: Fifty-six patients with newly diagnosed multiple myeloma and biopsy-proven renal lesions were enrolled. Kidney biopsies were reanalyzed, and the baseline clinical characteristics, treatments and outcomes were recorded. Results: Fifty-one patients had monoclonal immunoglobulin-associated renal lesions, with myeloma cast nephropathy (MCN) being the most common pattern. We divided our cohort into pure MCN, MCN+ other pathologies and non-MCN. Patients with MCN had more severe renal injury than those with non-MCN. In our cohort, none of the patients with pure MCN or MCN + other pathologies presented with nephrotic syndrome. Patients with non-MCN had better renal and overall survival than those with pure MCN but similar survivals to those with MCN + other pathologies. Number of myeloma casts (HR 1.08, p = 0.012) was the only independent prognostic factor for renal survival. Male sex (HR: 3.64; p = 0.015) and number of casts (HR: 1.17; p = 0.001) were independent prognostic factors for overall survival. Conclusion: Patients with MCN had more severe renal injury than those with non-MCN. Patients with non-MCN had better renal and overall outcomes than those with pure MCN, but their outcomes were similar to those with MCN + other pathologies. The independent predictors of overall survival were male sex and number of myeloma casts.
- Open Access
- 10 July 2020
- Published by Oxford University Press (OUP) in Microscopy
- Vol. 69 (6) , 381-390
Insulin protects against type 1 diabetes mellitus-induced ultrastructural abnormalities of pancreatic islet microcirculation
Pancreatic islet microcirculation, consisting of pancreatic islet microvascular endothelial cells (IMECs) and pericytes (IMPCs), provides crucial support for the physiological function of pancreatic islet. Emerging evidence suggests that pancreatic islet microcirculation is impaired in type 1 diabetes mellitus (T1DM). Here, we investigated the potential ultrastructural protective effects of insulin against streptozotocin (STZ)-induced ultrastructural abnormalities of the pancreatic islet microcirculation in T1DM mouse model. For this purpose, pancreatic tissues were collected from control, STZ-induced T1DM and insulin-treated mice, and a pancreatic IMECs cell line (MS1) was cultured under control, 35 mM glucose with or without 10−8 M insulin conditions. Transmission and scanning electron microscopies were employed to evaluate the ultrastructure of the pancreatic islet microcirculation. We observed ultrastructural damage to IMECs and IMPCs in the type 1 diabetic group, as demonstrated by destruction of the cytoplasmic membrane and organelles (mainly mitochondria), and this damage was substantially reversed by insulin treatment. Furthermore, insulin inhibited collagenous fiber proliferation and alleviated edema of the widened pancreatic islet exocrine interface in T1DM mice. We conclude that insulin protects against T1DM-induced ultrastructural abnormalities of the pancreatic islet microcirculation.
- 10 July 2020
- Published by Oxford University Press (OUP) in Microscopy
- Vol. 69 (6) , 381-390
Open AccessInsulin protects against type 1 diabetes mellitus-induced ultrastructural abnormalities of pancreatic islet microcirculation
Pancreatic islet microcirculation, consisting of pancreatic islet microvascular endothelial cells (IMECs) and pericytes (IMPCs), provides crucial support for the physiological function of pancreatic islet. Emerging evidence suggests that pancreatic islet microcirculation is impaired in type 1 diabetes mellitus (T1DM). Here, we investigated the potential ultrastructural protective effects of insulin against streptozotocin (STZ)-induced ultrastructural abnormalities of the pancreatic islet microcirculation in T1DM mouse model. For this purpose, pancreatic tissues were collected from control, STZ-induced T1DM and insulin-treated mice, and a pancreatic IMECs cell line (MS1) was cultured under control, 35 mM glucose with or without 10−8 M insulin conditions. Transmission and scanning electron microscopies were employed to evaluate the ultrastructure of the pancreatic islet microcirculation. We observed ultrastructural damage to IMECs and IMPCs in the type 1 diabetic group, as demonstrated by destruction of the cytoplasmic membrane and organelles (mainly mitochondria), and this damage was substantially reversed by insulin treatment. Furthermore, insulin inhibited collagenous fiber proliferation and alleviated edema of the widened pancreatic islet exocrine interface in T1DM mice. We conclude that insulin protects against T1DM-induced ultrastructural abnormalities of the pancreatic islet microcirculation.
- 1 September 2019
- Published by Elsevier in Microbial Pathogenesis
- Vol. 134, 103562
Therapeutic effectiveness of type I interferon in vulvovaginal candidiasis
- 1 September 2019
- Published by Elsevier in Microbial Pathogenesis
- Vol. 134, 103562
Therapeutic effectiveness of type I interferon in vulvovaginal candidiasis
- Open Access
- 8 May 2019
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 10, 1033
Local Probiotic Lactobacillus crispatus and Lactobacillus delbrueckii Exhibit Strong Antifungal Effects Against Vulvovaginal Candidiasis in a Rat Model
A comprehensive knowledge of the vaginal ecosystem is critical for the development of successful approaches to the treatment of infections. The role of Lactobacilli in preventing vulvovaginal candidiasis (VVC) is controversial. In this study, we investigated the therapeutic effects and mechanism of Lactobacillus crispatus or delbrueckii on vaginitis caused by Candida albicans in a Sprague–Dawley rat model. A microbiological evaluation was performed by Gram staining and fungal colonies were enumerated. The antifungal efficacy of the two Lactobacillus strains was assessed by hematoxylin and eosin (HE) staining, transmission electron microscopy (TEM), immunohistochemical detection of interferon-γ (IFN-γ), interleukin (IL)-4, IL-17, and epithelial-derived IgG (RP125). Our in vitro results showed that the inhibitory activity against Candida colony-forming unit (CFU) counts was demonstrated by the two Lactobacillus strains (P < 0.001). Our results indicated that Lactobacillus administration played an indispensable role in maintaining the immune homeostasis, and decreasing the Th1/Th2 ratio (IFN-γ/IL-4) by regulating the epithelial secretion of cytokines that inhibit epithelial proinflammatory cytokine release, while increasing epithelial-derived IgG expression (P < 0.05), suggesting antibody-mediated protection. Our results implicate L. crispatus and L. delbrueckii as a potential adjunct biotherapeutic agent in women with VVC, especially for those with drug resistance, adverse effects or contraindications when using antifungal agents. Further large, long-term, well-planned clinical studies should be performed in clinical practice to determine their clinical potential of L. crispatus and L. delbrueckii as an adjunct treatment for VVC.
- 8 May 2019
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 10, 1033
Open AccessLocal Probiotic Lactobacillus crispatus and Lactobacillus delbrueckii Exhibit Strong Antifungal Effects Against Vulvovaginal Candidiasis in a Rat Model
A comprehensive knowledge of the vaginal ecosystem is critical for the development of successful approaches to the treatment of infections. The role of Lactobacilli in preventing vulvovaginal candidiasis (VVC) is controversial. In this study, we investigated the therapeutic effects and mechanism of Lactobacillus crispatus or delbrueckii on vaginitis caused by Candida albicans in a Sprague–Dawley rat model. A microbiological evaluation was performed by Gram staining and fungal colonies were enumerated. The antifungal efficacy of the two Lactobacillus strains was assessed by hematoxylin and eosin (HE) staining, transmission electron microscopy (TEM), immunohistochemical detection of interferon-γ (IFN-γ), interleukin (IL)-4, IL-17, and epithelial-derived IgG (RP125). Our in vitro results showed that the inhibitory activity against Candida colony-forming unit (CFU) counts was demonstrated by the two Lactobacillus strains (P < 0.001). Our results indicated that Lactobacillus administration played an indispensable role in maintaining the immune homeostasis, and decreasing the Th1/Th2 ratio (IFN-γ/IL-4) by regulating the epithelial secretion of cytokines that inhibit epithelial proinflammatory cytokine release, while increasing epithelial-derived IgG expression (P < 0.05), suggesting antibody-mediated protection. Our results implicate L. crispatus and L. delbrueckii as a potential adjunct biotherapeutic agent in women with VVC, especially for those with drug resistance, adverse effects or contraindications when using antifungal agents. Further large, long-term, well-planned clinical studies should be performed in clinical practice to determine their clinical potential of L. crispatus and L. delbrueckii as an adjunct treatment for VVC.
- Open Access
- 25 October 2018
- Published by Springer Nature in BMC Microbiology
- Vol. 18 (1) , 1-11
Nystatin enhances the immune response against Candida albicans and protects the ultrastructure of the vaginal epithelium in a rat model of vulvovaginal candidiasis
Vulvovaginal candidiasis (VVC) is a common infectious disease of the lower genital tract. Nystatin, a polyene fungicidal antibiotic, is used as a topical antifungal agent for VVC treatment. The aim of the current study was to investigate the possible immunomodulatory effects of nystatin on the vaginal mucosal immune response during Candida albicans infection and examine its role in protection of vaginal epithelial cell (VEC) ultrastructure. Following infection with C. albicans, IFN-γ and IL-17 levels in VECs were significantly elevated, while the presence of IgG was markedly decreased as compared to uninfected controls (P < 0.05). No significant differences in IL4 expression were observed. After treatment with nystatin, the level of IFN-γ, IL-17 and IgG was dramatically increased in comparison to the untreated group (P < 0.05). Transmission electron microscopy revealed that C. albicans invades the vaginal epithelium by both induced endocytosis and active penetration. Nystatin treatment protects the ultrastructure of the vaginal epithelium. Compared with the untreated C. albicans-infected group, Flameng scores which measure mitochondrial damage of VECs were markedly decreased (P < 0.001) and the number of adhesive and invasive C. albicans was significantly reduced (P < 0.01) after treatment with nystatin. Nystatin plays a protective role in the host defense against C. albicans by up-regulating the IFN-γ-related cellular response, the IL-17 signaling pathway and possibly through enhancing VEC-derived IgG-mediated immunity. Furthermore, nystatin notably improves the ultramorphology of the vaginal mucosa, partially through the protection of mitochondria ultrastructure in VECs and inhibition of adhesion and invasion by C. albicans. Together, these effects enhance the immune response of the vaginal mucosa against C. albicans and protect the ultrastructure of vaginal epithelium in VVC rats.
- 25 October 2018
- Published by Springer Nature in BMC Microbiology
- Vol. 18 (1) , 1-11
Open AccessNystatin enhances the immune response against Candida albicans and protects the ultrastructure of the vaginal epithelium in a rat model of vulvovaginal candidiasis
Vulvovaginal candidiasis (VVC) is a common infectious disease of the lower genital tract. Nystatin, a polyene fungicidal antibiotic, is used as a topical antifungal agent for VVC treatment. The aim of the current study was to investigate the possible immunomodulatory effects of nystatin on the vaginal mucosal immune response during Candida albicans infection and examine its role in protection of vaginal epithelial cell (VEC) ultrastructure. Following infection with C. albicans, IFN-γ and IL-17 levels in VECs were significantly elevated, while the presence of IgG was markedly decreased as compared to uninfected controls (P < 0.05). No significant differences in IL4 expression were observed. After treatment with nystatin, the level of IFN-γ, IL-17 and IgG was dramatically increased in comparison to the untreated group (P < 0.05). Transmission electron microscopy revealed that C. albicans invades the vaginal epithelium by both induced endocytosis and active penetration. Nystatin treatment protects the ultrastructure of the vaginal epithelium. Compared with the untreated C. albicans-infected group, Flameng scores which measure mitochondrial damage of VECs were markedly decreased (P < 0.001) and the number of adhesive and invasive C. albicans was significantly reduced (P < 0.01) after treatment with nystatin. Nystatin plays a protective role in the host defense against C. albicans by up-regulating the IFN-γ-related cellular response, the IL-17 signaling pathway and possibly through enhancing VEC-derived IgG-mediated immunity. Furthermore, nystatin notably improves the ultramorphology of the vaginal mucosa, partially through the protection of mitochondria ultrastructure in VECs and inhibition of adhesion and invasion by C. albicans. Together, these effects enhance the immune response of the vaginal mucosa against C. albicans and protect the ultrastructure of vaginal epithelium in VVC rats.